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Abstract 18 
The most frequent missense mutations in familial Parkinson’s disease (PD) occur in the highly 19 
conserved LRRK2/PARK8 gene with G2019S mutation. We previously established a fly model of PD 20 
carrying the LRRK2-G2019S mutation that exhibited the parkinsonism-like phenotypes. An herbal 21 
medicine—Gastrodia elata Blume (GE), has been reported to have neuroprotective effects in toxin-22 
induced PD models. However, the underpinning molecular mechanisms of GE beneficiary to G2019S-23 
induced PD remain unclear. Here, we show that these G2019S flies treated with water extracts of GE 24 
(WGE) and its bioactive compounds, gastrodin and 4-HBA, displayed locomotion improvement and 25 
dopaminergic neuron protection. WGE suppressed the accumulation and hyperactivation of G2019S 26 
proteins in dopaminergic neurons, and activated the antioxidation and detoxification factor Nrf2 mostly in 27 
the astrocyte-like and ensheathing glia. Glial activation of Nrf2 antagonizes G2019S-induced Mad/Smad 28 
signaling. Moreover, we treated LRRK2-G2019S transgenic mice with WGE and found the locomotion 29 
declines, the loss of dopaminergic neurons, and the number of hyperactive microglia were restored. WGE 30 
also suppressed the hyperactivation of G2019S proteins and regulated the Smad2/3 pathways in the mice 31 
brains. We conclude that WGE prevents locomotion defects and the neuronal loss induced by G2019S 32 
mutation via glial Nrf2/Mad signaling, unveiling a potential therapeutic avenue for PD. 33 
  34 
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Introduction 35 
Parkinson’s disease (PD) is a highly prevalent neurodegenerative disorder characterized by the loss 36 
of dopaminergic neurons in the substantia nigra projecting to the striatum of the basal ganglion, 37 
representing a circuit involved in motor planning and coordination. As a consequence, PD is associated 38 
with motor abnormalities, bradykinesia, hypokinesia, rigidity and resting tremor. Currently, the most 39 
frequently applied pharmacological treatment, levodopa (L-DOPA), exerts limited motor improvement 40 
and elicits negative side-effects (Ray Chaudhuri et al., 2018). Hence, identifying and developing 41 
alternative or complementary treatments may assist in mitigating PD progression. 42 
PD is a multi-causal disease with a complicated etiology, including familial inheritance. More than 43 
20 PARK genes have been genetically linked to PD, a number that is increasing (Houlden & Singleton, 44 
2012). Missense mutations in PARK8, or Leucine-rich repeat kinase 2 (LRRK2) induce characteristic PD 45 
symptoms and pathologies such as loss of dopaminergic neurons and the appearance of Lewy bodies 46 
(Martin et al., 2014). Notably, the most commonly observed mutation, dominant G2019S, among familial 47 
PD cases is located in the kinase domain of Lrrk2, which augments its kinase activity via auto- and hyper-48 
activation (Sheng et al., 2012). The hyperactive G2019S mutant protein alters several cellular processes, 49 
including vesicle trafficking, microtubule dynamics, autophagy, mitochondrial function (Martin et al., 50 
2014), and most commonly, increases susceptibility to oxidative stress that contributes to neuronal 51 
degeneration (Angeles et al., 2011; Nguyen et al., 2011). These indicate that regulation of the 52 
hyperactivation of G2019S mutant protein appears to be a disease-modifying strategy. 53 
Glia provide structural and metabolic supports to neurons and regulate synaptic transmissions, so 54 
they are important for the function and survival of dopaminergic neurons (Lin et al., 1993; Sofroniew & 55 
Vinters, 2010). Dysfunction in two major glial types, astrocytes and microglia, contribute to the onset and 56 
progression of both sporadic and familial PD (Kam et al., 2020). Astrocytes and microglia of postmortem 57 
PD brains exhibit pathologic lesions and hyper-immunoactivity (Miklossy et al., 2006). A clinical trial 58 
involving down-regulation of microglial oxidative stress highlights the significance of glia to PD (Jucaite 59 
et al., 2015). Moreover, Lrrk2 regulates the inflammatory response in microglia and the autophagy-60 
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lysosome pathway in astrocytes, with the G2019S mutation altering the size and pH of lysosomes (Henry 61 
et al., 2015; Moehle et al., 2012). Expression of G2019S mutant protein in neurons was previously shown 62 
to induce the secretion of Glass bottom boat (Gbb)/bone morphogenetic protein (BMP) signal that, in 63 
turn, upregulates Mothers against decapentaplegic (Mad)/Smad signaling in glia, which prompts feedback 64 
signals to promote neuronal degeneration (Maksoud et al., 2019). These studies indicate that G2019S 65 
mutant protein alters the homeostasis and interaction between neurons and glia, contributing to PD 66 
pathogenesis. However, whether any dietary or pharmacological treatment blockading this neuron-glia 67 
interaction beneficiary to G2019S-induced PD is unclear. 68 
Given that up to 70% of human PARK genes are conserved in the Drosophila genome, Drosophila is 69 
frequently used as a PD model for studying gene function, such as the PARK1/SNCA (Chen & Feany, 70 
2005) and PARK8/LRRK2 (Liu et al., 2008). Genetic and molecular linkage between PINK1/PARK6 and 71 
Parkin/PARK2 was first established in Drosophila (Clark et al., 2006). When overexpressed in 72 
Drosophila dopaminergic neurons, LRRK2 transgenes carrying G2019S or other dominant mutations 73 
induce dopaminergic neuron loss and locomotion impairment, two age-dependent symptoms of PD (Lin 74 
et al., 2010; Liu et al., 2008). The G2019S model has further been used to screen a collection of FDA-75 
approved drugs to suppress these PD phenotypes. Thus, Drosophila represents an amenable model of PD 76 
for genetic, molecular and pharmacological study of potential therapeutic interventions. Strikingly, 77 
lovastatin was found to prevent dendrite degeneration, dopaminergic neuron loss, and impaired 78 
locomotion and, critically, a lovastatin-involved Nrf2 pathway proved neuroprotective (C. H. Lin et al., 79 
2016). Nevertheless, whether the Nrf2-mediated neuroprotection is cell- or non-cell-autonomous, 80 
remaining elusive. 81 
Traditional Chinese Medicine (TCM) is often used as an alternative or dietary treatment for human 82 
diseases, including PD (Kim et al., 2012; Li et al., 2017). Although the results were inconclusive, some 83 
TCM could display adjuvant effects when used in combination with L-DOPA, reducing the L-DOPA 84 
dosage required in long-term treatments and relieving non-motor symptoms (Kim et al., 2012). As a 85 
prominent component in TCM, Gastrodia elata Blume (GE; Orchidaceae) has been used to treat 86 
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neurological disorders for centuries (Chen & Sheen, 2011). GE has been shown to exert neuroprotective, 87 
anti-inflammatory and antioxidative effects in neurodegenerative disease models (Jang et al., 2015). The 88 
major bioactive compounds in GE include gastrodin and 4-hydroxybenzyl alcohol (4-HBA), both of 89 
which display pharmacological effects on neurobiological and psychological disorders (Chen et al., 2016; 90 
Kumar et al., 2013). Additionally, gastrodin and 4-HBA have been reported to activate the Nrf2 signaling 91 
in dopaminergic neurons and astrocytes, respectively (Jiang et al., 2014; Luo et al., 2017), highlighting a 92 
potential benefit of incorporating GE in PD treatments. However, the effects and mechanisms underlying 93 
how GE moderate Lrrk2-G2019S PD remain unclear.   94 
In the present study, we treated G2019S animals with water extract of GE (WGE), and its bioactive 95 
compounds, gastrodin and 4-HBA. We have investigated the impact of WGE treatment on PD in restoring 96 
locomotion and protecting dopaminergic neurons in the Drosophila G2019S model. We identified two 97 
distinct pathways induced by WGE in the model, i.e., suppression of Lrrk2 protein accumulation and 98 
hyperphosphorylation in neurons, and activation of the Nrf2 pathway in glia, particularly in astrocyte-like 99 
and ensheathing glia. We show that WGE-induced Nrf2 activation antagonizes the Gbb-activated Mad 100 
signaling in glia, contributing to neuronal protection. WGE also suppressed the hyperactivation of 101 
G2019S proteins and antagonized Smad2/3 signaling in a LRRK2-G2019S mouse model, which restored 102 
locomotion, protected dopaminergic neurons and regulated the microglia hyperactivation. Conservation 103 
of the pathways impacted by WGE treatment in both the Drosophila and mouse G2019S models implies 104 
that the beneficial effects of GE and represent a reliable and effective complementary therapy for PD.  105 
  106 
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Results  107 
WGE treatment improves locomotion of Ddc>G2019S flies  108 
We employed the GAL4-UAS system to express the human G2019S mutant of Lrrk2 by the Ddc-109 
GAL4 driver (Ddc>G2019S) in dopaminergic neurons and then assessed the anti-geotactic climbing 110 
activity of adult flies. We observed that locomotion of Ddc>G2019S flies was affected significantly 111 
relative to control flies expressing human wild-type Lrrk2 (Ddc>Lrrk2) (Figure 1A and Figure 1-figure 112 
supplement 1A). At weeks 1 and 2, more than 80% of Ddc>G2019S flies could successfully climb above 113 
an 8-cm threshold, a proportion comparable to that of Ddc>Lrrk2 flies. However, the success rate 114 
declined to ~40% at week 3, ~20% at week 4, and to less than 10% at weeks 5 and 6. These proportions 115 
are significantly lower than the ~80% at week 3, ~60% at week 4, and ~40% at weeks 5 and 6 displayed 116 
by Ddc>Lrrk2 flies. Although both Ddc>G2019S and Ddc>Lrrk2 flies failed to reach the 8-cm mark at 117 
weeks 7 and 8, Ddc>Lrrk2 flies could still climb the wall, whereas almost all Ddc>G2019S flies could 118 
not (Figure 1-figure supplement 1A). We also tested the climbing activity of another control expressing 119 
GFP in dopaminergic neurons (Ddc>mCD8-GFP). Both Ddc>Lrrk2 and Ddc>mCD8-GFP flies showed 120 
comparable climbing activities in the first six weeks, and a significant number of Ddc>mCD8-GFP flies 121 
were still able to climb above the 8-cm mark at week 7. Therefore, we used the Ddc>Lrrk2 line as a 122 
control for Ddc>G2019S flies in subsequent experiments to dissect the specific mode of pathogenicity of 123 
the G2019S mutation.   124 
Next, we examined the effect of feeding flies with water extracts of GE (WGE) as a dietary 125 
supplement at different concentrations (0.1, 0.5 or 1.0%, w/w). WGE treatment of Ddc>G2019S flies at 126 
all three doses elicited a significant improvement in their climbing ability (Figure 1A). Strikingly, the 127 
lowest concentration (0.1%) of WGE proved the most effective, with Ddc>G2019S flies still performing 128 
well at climbing (i.e., comparably to Ddc>Lrrk2 control flies) in weeks 5 and 6. The higher doses of 129 
WGE (0.5 % and 1.0%) still exerted beneficial effects at weeks 3 and 4, albeit not as significantly as the 130 
0.1% dose, but had no beneficial effect in weeks 5 and 6. As 0.1% is the lowest among the three doses 131 
tested, we lowered the dose of WGE to 0.02% and found that 0.02% WGE was less effective than 0.1% 132 
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starting at week 3 till week 6, suggesting that 0.1% is the optimal dose in restoring the climbing activity 133 
of Ddc>G2019S flies (Figure 1-figure supplement 1B). We also tested the WGE effect on the 134 
Ddc>G2019S flies that were fed with regular food without WGE for 3 weeks. At week 4, these 135 
Ddc>G2019S flies also showed a significant improvement in their climbing ability, compared to the age-136 
matched Ddc>G2019S flies fed continuously on regular food (Figure 1-figure supplement 2). The effect 137 
of improving climbing activity in the WGE-fed Ddc>G2019S flies was reduced at week 5 and diminished 138 
at week 6, suggesting that WGE feeding starting at earlier stages is important for long-term locomotion 139 
improvement. 140 
Gastrodin and 4-HBA are two major phenolic compounds in GE displaying neuropharmacological 141 
effects (Zhan et al., 2016). Feeding Ddc>G2019S flies with food containing gastrodin (0.1 mM) 142 
equivalent to the amount in 0.1% WGE also restored locomotion of Ddc>G2019S flies in weeks 2-4, 143 
though its impact diminished to non-significant levels at weeks 5 and 6. However, increasing the 144 
gastrodin dose ten-fold (1.0 mM) resulted in improved climbing activity at weeks 5 and 6 (Figure 1B). 145 
Similarly, the equivalent 0.1 mM of 4-HBA, the aglyconic form of gastrodin and the bioactive form in the 146 
brain (Wu et al., 2017), was sufficient to restore the climbing ability of Ddc>G2019S flies, and a ten-fold 147 
dose at 1.0 mM had an even better effect (Figure 1C). These results indicate that both gastrodin and 4-148 
HBA are primary bioactive compounds in GE that prevent locomotion decline in Ddc>G2019S flies, and 149 
higher doses are more beneficial to reach the effect as WGE did. 150 
Success in the anti-gravity wall-climbing assay also requires an immediate response to startle 151 
knockdown. Accordingly, we performed a second assay, free-walking in an open arena, to assess 152 
improved locomotion. Consistently, free-walking by Ddc>G2019S flies was greatly impaired, with total 153 
walking distance reduced to less than 20% that displayed by control Ddc>Lrrk2 flies (Figure 1D). 154 
Moreover, Ddc>G2019S flies displayed centrophobism, i.e., they avoided walking into the central open 155 
space. Strikingly, 0.1% WGE feeding greatly extended walking distance and suppressed the 156 
centrophobism of Ddc>G2019S flies. Together, these two assays strongly indicate that the defective 157 
locomotion exhibited by Ddc>G2019S flies is greatly improved by feeding them with 0.1% WGE. 158 
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Because the improvement on the locomotion was more effective in flies fed with 0.1% WGE than the 159 
pure compounds, we therefore fed the flies with 0.1% WGE in the following experiments. 160 
   161 
WGE treatment suppresses dopaminergic neuron loss in Ddc>G2019S brain   162 
Expression of G2019S mutant protein has been shown to induce a gradual loss of dopaminergic 163 
neurons in the adult fly brain, contributing to impaired locomotion (Lin et al., 2010; Liu et al., 2008). 164 
Several clusters of dopaminergic neurons have been identified in the adult brain of Drosophila. Here, we 165 
focused on the PPL1, PPL2, PPM1/2 and PPM3 clusters that have well-defined roles in modulating 166 
locomotion (Mao & Davis, 2009) to assess the effect of WGE treatment. We detected reduced numbers of 167 
dopaminergic neurons in the PPL1, PPL2, PPM1/2, and PPM3 clusters of Ddc>G2019S flies relative to 168 
Ddc>Lrrk2 controls, which increased in severity from week 2 to 6 (Figure 2 and Figure 2-figure 169 
supplement 1A to C). Consistently, feeding Ddc>G2019S flies with 0.1% WGE restored numbers of 170 
dopaminergic neurons in these clusters to the levels observed in controls (Figure 2 and Figure 2-figure 171 
supplement 1A to C). Thus, concomitant rescue of locomotion and dopaminergic neuron populations in 172 
Ddc>G2019S flies indicates that WGE treatment likely promotes dopaminergic neuron survival to restore 173 
locomotion. 174 
 175 
WGE treatment suppresses G2019S-induced Lrrk2 hyperactivation 176 
The enhanced survival of dopaminergic neurons due to WGE treatment implies that WGE induces 177 
neuroprotective mechanisms in Ddc>G2019S flies. The G2019S mutation causes Lrrk2 178 
hyperphosphorylation, protein accumulation, and aberrant cellular signaling (Price et al., 2018). 179 
Therefore, we explored if WGE-induced neuroprotection is responsible for abrogating these processes in 180 
G2019S flies. We detected comparable levels of Lrrk2 proteins in 3-day-old adult brains pan-neuronally 181 
expressing wild-type Lrrk2 (elav>Lrrk2) or G2019S mutant protein (elav>G2019S) (Figure 3A). 182 
However, phosphorylation levels at the Ser1292 autophosphorylation site was higher in the elav>G2019S 183 
flies compared to elav>Lrrk2 (Figure 3A and B). This outcome was also observed at week 4 (Figure 3F 184 
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and G), consistent with the idea that Lrrk2 is hyperactivated upon G2019S mutation. 185 
Hyperphosphorylation in elav>G2019S flies led to Lrrk2 protein accumulation, as determined by total 186 
Lrrk2 levels at weeks 2 and 4 (Figure 3D and E). However, both hyperphosphorylation and protein 187 
accumulation were suppressed upon feeding elav>G2019S flies with 0.1% WGE (Figure 3D to G). In the 188 
elav>Lrrk2 control, WGE feeding had no effect on levels of wild-type Lrrk2 or Ser1292 phosphorylation 189 
(Figure 3-figure supplement 1A to C). We further examined the G2019S mutant-activated downstream 190 
effector Rab10, the phosphorylation status of which can serve as an indicator of Lrrk2 kinase activity 191 
(Karayel et al., 2020). We observed that levels of phosphorylated Rab10 were increased in elav>G2019S 192 
flies, but this phenotype was suppressed by WGE feeding (Figure 3F and H). Hence, feeding flies with 193 
WGE suppresses G2019S-induced Lrrk2 protein phosphorylation, accumulation, and signaling. 194 
 195 
WGE treatment restores Akt/GSK3β/Nrf2 pathway activity 196 
The Akt/GSK3β/Nrf2 signaling axis has been shown to promote survival of dopaminergic neurons 197 
and ameliorate motor dysfunction in PD models (C. H. Lin et al., 2016). We assayed the phosphorylation 198 
status of Akt at Ser505 in 3-day-old adult fly head extracts and found reduced levels of pAkt in 199 
elav>G2019S flies relative to elav>Lrrk2 controls (Figure 3A and C). This pAkt reduction persisted at 200 
weeks 2 and 4, but was abrogated by feeding elav>G2019S flies with 0.1% WGE (Figure 4A and B). We 201 
also examined phosphorylation levels of Nrf2 at Ser40 and GSK3β at Ser9, both of which were reduced 202 
upon expression of G2019S mutant protein and were equally offset by WGE feeding (Figure 4C and D). 203 
Induction of Akt/GSK3β/Nrf2 signaling activates expression of heme oxygenase 1 (HO-1), and we 204 
observed diminished levels of this latter protein in elav>G2019S flies, which could be rescued by WGE 205 
feeding (Figure 4C and D). Therefore, WGE feeding restores the Akt/GSK3β/Nrf2 signaling activity 206 
compromised by the G2019S mutation. 207 
 208 
Glial Nrf2 mediates the beneficial effect of WGE on restored locomotion and neuronal protection in 209 
G2019S flies 210 
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    Restoration of Akt/GSK3β/Nrf2 signaling activity by WGE treatment prompted us to test by genetic 211 
assays if that signaling pathway mediates the WGE mode of action. We focused on the downstream 212 
effector Nrf2 encoded by cap-n-collar (cnc) in Drosophila. Intriguingly, neither overexpression (UAS-213 
cncC-FL2) nor RNAi knockdown (UAS-cncTRiP) of Nrf2 in dopaminergic neurons had an impact on the 214 
climbing ability of Ddc>G2019S flies (Figure 5A). Also, WGE feeding still rescued locomotion of 215 
Ddc>G2019S flies with Nrf2 knockdown (Ddc>G2019S; cncTRiP) to levels comparable to WGE-fed 216 
control flies (Ddc>G2019S; mCD8-GFP) without Nrf2 knockdown (Figure 5A). Thus, the Nrf2 pathway 217 
activation by WGE that appears to be effective in protecting neurons and restoring locomotion is likely 218 
exerted in cells other than neurons.  219 
Nrf2 activation may be examined by assessing GFP signal from the ARE-GFP reporter that harbors 220 
Nrf2 binding sites and responds to Nrf2 activation (Chatterjee & Bohmann, 2012). ARE-GFP adult fly 221 
brains displayed low basal GFP signals (Figure 5-figure supplement 1A), but feeding with 0.1% WGE 222 
elicited many GFP-positive signals in Repo-positive glia (arrowheads in Figure 5-figure supplement 1B), 223 
evidencing that glia may be the primary cell type in which Nrf2 is activated. 224 
Next, we investigated if WGE-induced Nrf2 activity in glia is effective in promoting locomotion in 225 
G2019S flies. To this end, we employed the LexA-LexAop system to overexpress wild-type Lrrk2 or 226 
G2019S mutant protein in dopaminergic neurons (Ddc-LexA>Lrrk2 and Ddc-LexA>G2019S, 227 
respectively), and used the GAL4 driver to manipulate Nrf2/CncC activity in glia (repo>cncC-FL2 for 228 
overexpression and repo>cnc-RNAi for knockdown). As a first step, we validated the age-dependent 229 
locomotion decline of Ddc-LexA>G2019S flies that was severer than Ddc-LexA>Lrrk2 and could be 230 
rescued by 0.1% WGE feeding (Figure 5-figure supplement 2). We then assayed the climbing ability of 231 
Ddc-LexA>G2019S flies exhibiting repo-GAL4-driven Nrf2 overexpression in glia (Ddc-LexA>G2019S; 232 
repo>cncC-FL2). Significantly, the Ddc-LexA>G2019S; repo>cncC-FL2 flies performed better in the 233 
climbing assay than Ddc-LexA>G2019S; repo-GAL4 without Nrf2 overexpression (Figure 5B). We also 234 
performed Nrf2 knockdown in glia (Ddc-LexA>G2019S; repo>cnc-RNAi), which had little impact on the 235 
already declined climbing activity in Ddc-LexA>G2019S; repo-GAL4 (Figure 5B). Importantly, WGE 236 
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feeding could not rescue locomotion deficits of glial Nrf2-knockdown flies (Ddc-LexA>G2019S; 237 
repo>cnc-RNAi) (Figure 5B, compare to Ddc-LexA>G2019S; repo-GAL4 with WGE feeding). Thus, 238 
glial overexpression of Nrf2 partially restores locomotion of Ddc-LexA>G2019S flies, and glial depletion 239 
of Nrf2 abolishes the ability of WGE to rescue impaired locomotion. 240 
We stained dopaminergic neurons of 6-week-old adult fly brains and confirmed that numbers of TH-241 
positive dopaminergic neurons in the PPL1 cluster were reduced in the Ddc-LexA>G2019S; repo-GAL4 242 
flies compared to Ddc-LexA>Lrrk2; repo-GAL4 controls (Figure 5C and D). Importantly, numbers of 243 
dopaminergic neurons in the PPL1 cluster were restored upon glial overexpression of Nrf2 in the Ddc-244 
LexA>G2019S; repo>cncC-FL2 flies. In contrast, glial Nrf2 knockdown had little impact on the already 245 
reduced dopaminergic neurons. Taken together, these results support that glial Nrf2 is compromised in 246 
Ddc-LexA>G2019S flies, and glial expression of Nrf2 protects the dopaminergic neurons. 247 
Although WGE feeding suppressed hyperactivity of G2019S mutant protein (Figure 3D to G), it was 248 
not clear if WGE-mediated Nrf2 activation in glia could directly suppress mutant protein hyperactivity in 249 
dopaminergic neurons. To test this possibility, we compared the levels of total Lrrk2 protein and 250 
phosphorylated Lrrk2 protein in Ddc-LexA>G2019S with and without glial Nrf2 overexpression (Ddc-251 
LexA>G2019S; repo-GAL4 and Ddc-LexA>G2019S; repo>cncC). We observed comparable levels of 252 
Lrrk2 and pLrrk2 in the control and Nrf2 overexpression lines (Figure 6-figure supplement 1A to C). 253 
Thus, the neuroprotective effects of Nrf2 activity are unlikely to operate through modulation of Lrrk2 254 
levels or activity. 255 
 256 
Nrf2 in astrocyte-like and ensheathing glia are the major targets of WGE that alleviate Lrrk2-257 
G2019S locomotion deficits 258 
Five types of glia with different morphologies and functions have been identified in the fly brain 259 
(Freeman, 2015). We decided to identify specific subtypes of glia that may mediate the WGE-induced 260 
Nrf2 activity endowing neuronal protection, given that dysfunctional astrocytes and microglia have been 261 
linked to onset and progression of both sporadic and familial PD (Kam et al., 2020). In Ddc-262 
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LexA>G2019S flies, GAL4-driven cnc knockdown in astrocyte-like (Ddc-LexA>G2019S; alrm>cnc-263 
RNAi) or ensheathing glia (Ddc-LexA>G2019S; R56F03>cnc-RNAi) abolished the improved locomotion 264 
elicited by WGE treatment, recapitulating the effect of pan-glial Nrf2 knockdown (Ddc-LexA>G2019S; 265 
repo>cnc-RNAi) (Figure 6A). This outcome was not observed when we used GAL4 drivers to knock 266 
down cnc in cortex (np2222), perineurial (np6293), or subperineurial (moody) glia. We confirmed the 267 
involvement of astrocyte-like and ensheathing glia by means of Nrf2 overexpression in astrocyte-like 268 
(Ddc-LexA>G2019S; alrm>cncC-FL2) or ensheathing (Ddc-LexA>G2019S; R56F03>cncC-FL2) glia, 269 
with both treatments improving the climbing activity of Ddc-LexA>G2019S flies not subjected to WGE 270 
feeding (Figure 6B). These analyses indicate that WGE feeding induces Nrf2 activity in astrocyte-like 271 
and ensheathing glia, which mitigates the reduced locomotion displayed by G2019S mutant-expressing 272 
flies. 273 
Next, we assayed Nrf2-regulated ARE-GFP expression in astrocyte-like and ensheathing glia of flies 274 
expressing G2019S mutant protein and subjected to WGE treatment. We focused on the astrocyte-like 275 
and ensheathing cells located adjacent to dopaminergic neurons. In control flies expressing wild-type 276 
Lrrk2, we detected basal levels of GFP signal in mCherry-positive astrocyte-like (alrm-GAL4) or 277 
ensheathing glia (R56F03) (Figure 6C to F). We detected lower levels of GFP signal in these cells when 278 
G2019S mutant protein was expressed in dopaminergic neurons. However, upon feeding with 0.1% 279 
WGE, we observed higher levels of GFP signal in both types of glia. Changes in the intensities of GFP 280 
signals were also detected in TH-positive dopaminergic neurons, although the levels were lower than in 281 
glia (Figure 6-figure supplement 2A and B). Thus, overexpression of G2019S mutant protein in 282 
dopaminergic neurons elicited reduced Nrf2 signaling activity, but WGE feeding restored or further 283 
enhanced Nrf2 activities in these two glial subtypes. 284 
 285 
Nrf2 activation antagonizes BMP signaling in glia 286 
G2019S mutant protein in dopaminergic neurons has been shown previously to enhance the 287 
expression of the proprotein convertase Furin 1 (Fur1) that processes the bone morphogenetic protein 288 
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(BMP) signaling molecule Glass bottom boat (Gbb) for maturation and release, leading to activation of 289 
the BMP signaling pathway in glia (Maksoud et al., 2019). We confirmed that finding by removing one 290 
copy of Mad that encodes the pathway’s downstream effector to restore locomotion in Ddc>G2019S flies 291 
(Figure 7-figure supplement 1). To address if WGE-induced Nrf2 activation could antagonize BMP 292 
signaling activity in glia, first we assessed expression of the phosphorylated Mad (pMad) activated by 293 
BMP signaling. In glia of Ddc>G2019S adult fly brains, pMad levels were higher than in Ddc>Lrrk2 294 
brains and they could be suppressed by WGE treatment (Figure 7A and B). Similar to the previous report 295 
(Maksoud et al., 2019), glial overexpression of Mad (UAS-Mad) or constitutively active type I receptor 296 
Tkv (UAS-tkvQ253D) was sufficient to impair locomotion, even without expressing G2019S mutant protein 297 
in neurons. However, impaired locomotion was rescued in both cases by 0.1% WGE feeding (Figure 7C 298 
and D). In addition, numbers of dopaminergic neurons in the PPL1 cluster were reduced upon glial 299 
overexpression of Mad or tkvQ253D and they were restored by 0.1% WGE treatment (Figure 7E to H). 300 
Together, these analyses indicate that activation of BMP signaling in glia recapitulates the phenotypes 301 
observed in flies overexpressing G2019S mutant protein in dopaminergic neurons and, furthermore, that 302 
these effects can be suppressed by WGE treatment. 303 
Next, we explored if WGE-induced Nrf2 activation antagonizes BMP signaling in glia. Glial Nrf2 304 
overexpression in Ddc-LexA>G2019S flies (Ddc-LexA>G2019S; repo>cncC-FL2) partially rescued the 305 
locomotory impairment caused by G2019S mutation (Figure 5B), and removing one copy of Mad (Ddc-306 
LexA>G2019S, Mad
+/-
; repo>cncC-FL2) further enhanced this effect (Figure 8A). Indeed, this outcome 307 
was equivalent to removing one copy of Mad but without Nrf2 overexpression (Ddc-LexA>G2019S, 308 
Mad
+/-
; repo-GAL4), suggesting that Nrf2 functions mainly to antagonize Mad activity (Figure 8A). 309 
Consistently, Nrf2 overexpression in glia or WGE treatment suppressed the up-regulation of pMad levels 310 
in glia caused by G2019S mutant protein overexpression in dopaminergic neurons (Ddc-LexA>G2019S; 311 
repo-GAL4) (Figure 8B and C). Depletion of Nrf2 from glia (Ddc-LexA>G2019S; repo>cnc-RNAi), even 312 
in the presence of WGE treatment, maintained high pMad levels in glia (Figure 8B and C). Thus, 313 
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modulation of Nrf2 activity, either by genetic manipulation or by WGE treatment, has an antagonistic 314 
effect on pMad levels in glia.   315 
We also addressed if Mad modulates expression of the Nrf2 target ARE-GFP. We observed 316 
diminished GFP signal in PPL1-surrounding glia of Ddc-LexA>G2019S adult fly brains relative to the 317 
Ddc-LexA>Lrrk2 control. Heterozygosity of Mad in Ddc-LexA>G2019S flies (Ddc-LexA>G2019S, 318 
Mad
+/-) restored the level of GFP signal, implying that Mad modulates targeted gene expression induced 319 
by Nrf2 activity (Figure 8D and E). 320 
 321 
The effects of WGE treatment in a LRRK2-G2019S mouse model 322 
To further study the effect of WGE on G2019S mutation-induced neurodegeneration in a 323 
mammalian system, we fed LRRK2-G2019S transgenic mice with WGE starting at the age of 8.5 months, 324 
i.e., prior to onset of impairments in locomotion and dopaminergic neurons (Chou et al., 2014). We 325 
quantified three locomotor activities from video-tracking paths of an open-field test, i.e., accumulative 326 
moving distance, average velocity, and percentage of time moving (Figure 9A and B). At the age of 8.5 327 
months, three groups—non-transgenic (nTg), transgenic LRRK2-G2019S, and WGE-fed transgenic 328 
LRRK2-G2019S mice—presented comparable locomotor activities. At 9.5 months of age, the LRRK2-329 
G2019S mice displayed clearly impaired locomotion, which was statistically significant at the age of 11.5 330 
months relative to nTg littermates (Figure 9B), consistent with a previous report (Chen et al., 2012). 331 
Importantly, the LRRK2-G2019S mice fed with WGE showed improved locomotion throughout the 3-332 
month treatment period, an outcome that was statistically significant at 11.5 months (Figure 9A and B). 333 
WGE treatment also suppressed the centrophobism displayed by LRRK2-G2019S mice (Figure 9A). We 334 
also analyzed the gait of these three groups of mice (Figure 9C). Similar to our findings from the open 335 
field test, stride length of LRRK2-G2019S mice was significantly reduced at 11.5 months, but it was 336 
restored to the level of nTg mice by WGE feeding (Figure 9C and D). Collectively, these analyses show 337 
that WGE feeding is an effective means of restoring G2019S mutation-induced locomotory declines in 338 
this mouse model of PD. 339 
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Since the nigral-striatal system contributes to locomotor function, we counted the number of TH-340 
positive dopaminergic neurons in the substantia nigra. In comparison to nTg littermates, the number of 341 
dopaminergic neurons in 11.5-month-old LRRK2-G2019S mice was significantly reduced, but WGE 342 
treatment for three months abrogated this loss of dopaminergic neurons (Figure 10A and B). In the 343 
Ddc>G2019S Drosophila model, glia mediate the protective effects of WGE on dopaminergic neurons. 344 
We found that activated microglia marked by ionized calcium-binding adapter molecule 1 (Iba-1) were 345 
increased in the substantia nigra of LRRK2-G2019S mice, but this increase was suppressed by WGE 346 
treatment (Figure 10C and D, and Figure 10-figure supplement 1). We further analyzed levels of activated 347 
LRRK2 (pLRRK2) in lysates isolated from the nigra-striatum. Levels of pLRRK2 normalized to LRRK2 348 
signal were higher in LRRK2-G2019S mice than in nTg littermates, but WGE treatment partially 349 
abrogated that outcome (Figure 10E and F). Since G2019S mutation enhanced Mad signaling activation 350 
in the fly brain (Figure 8B and C), we also tested this scenario in the mouse model. Immunoblots revealed 351 
that the ratio of phosphorylated Smad2 to total Smad2 (pSmad2/Smad2) was significantly elevated in 352 
LRRK2-G2019S mice, but this increase was suppressed by WGE treatment (Figure 10E and G). 353 
Moreover, although the level of pSmad3/Smad3 was not significantly enhanced by G2019S mutant 354 
protein expression, it was suppressed by WGE treatment (Figure 10E and G). Thus, WGE feeding 355 
suppresses G2019S mutation-induced microglia activation and Smad signaling in the substantia nigra of 356 
the LRRK2-G2019S mouse model of PD. 357 
 In summary, the potential mechanisms of WGE involved in the modulation of the neuron-glial 358 
interaction are proposed (Figure 11). WGE regulates the hyperactivation of G2019S mutant protein in 359 
dopaminergic neurons, and antagonizes the Mad signaling by activating the Nrf2 pathway in glia. Both 360 
actions provide neuroprotection. 361 
  362 
 16 
Discussion  363 
Motor dysfunction in Drosophila neurodegeneration models has been frequently evaluated by means 364 
of negative-geotaxis assay that measures the insect innate response. The assay begins with a sudden 365 
external stimulation, which initially inhibits spontaneous locomotion but is followed by climbing 366 
behavior. The entire response requires motor circuit coordination and muscle tone regulation, two 367 
processes that progressively decline with age and that are impacted by neuropathological insults 368 
(Grotewiel et al., 2005). In contrast, the open-arena walking assay allows free exploration without 369 
disturbance, representing an assay for locomotor activities that can reveal deficits like bradykinesia (Chen 370 
et al., 2014). Our G2019S flies exhibited reduced locomotor activity in both assays. Moreover, the 371 
G2019S flies also exhibited centrophobism-like behavior in the open-arena (Figure 1D). Centrophobism 372 
is indicative of emotional abnormalities, such as anxiety and depression, both of which are often 373 
associated with PD (Kulisevsky et al., 2008), and was also displayed by the LRRK2-G2019S mice (Figure 374 
9A). WGE treatment suppresses centrophobism in both fly and mouse PD models has important 375 
implications for tackling major symptoms of PD and even non-PD-related depression, as reported for 376 
rodent models (Lin et al., 2018; Y. E. Lin et al., 2016). Thus, WGE treatment exerts beneficial effects in 377 
both of our PD models. 378 
We found that the 0.1% dosage of WGE is optimal in suppressing age-dependent locomotion decline 379 
in G2019S flies, with higher and lower doses being less effective (Figure 1A and Figure 1-figure 380 
supplement 1B). Although an inverted U-shaped drug response is common, a plausible explanation for the 381 
diminished effectiveness of higher doses is that WGE downregulates the day-time but not night-time 382 
locomotor activity of flies (Jo et al., 2017). In mice, higher WGE doses have sleep-promoting effects by 383 
activating adenosine A1/A2A receptors in the ventrolateral preoptic area (Zhang et al., 2012). Thus, 384 
dosage level is critical to the beneficial effects of GE in both PD models. 385 
Gastrodin and 4-HBA are considered the principal active components in GE (Zhan et al., 2016). 386 
Although both compounds can cross the blood-brain barrier (Wu et al., 2017), the capability of gastrodin 387 
to do so is relatively poor compared to aglyconic 4-HBA due to the glucose moiety (Lin et al., 2007). 388 
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Gastrodin is quickly metabolized to 4-HBA and undetermined metabolites in the brain (Lin et al., 2008), 389 
perhaps explaining the lower effectiveness of gastrodin in G2019S flies. However, it is likely that the 390 
combination of gastrodin with other components in GE might exert optimal beneficial effects. 391 
Expression of G2019S mutant protein impacts different clusters of dopaminergic neurons in the fly 392 
brain that are known for their connectivity and function. Activation of two specific mushroom body 393 
(MB)-projection dopaminergic neurons in the PPL1 cluster inhibits climbing performance (Sun et al., 394 
2018). Mutations in the circadian gene Clock (Clk) cause PPL1 dopaminergic neuron degeneration, 395 
accelerating impaired age-associated climbing ability (Vaccaro et al., 2017). Dopaminergic neurons in the 396 
PPL2 cluster extend processes to the calyx of the MB, which has been linked to climbing activity (Sun et 397 
al., 2018). In contrast, PPM3 neurons project to the central complex, activation of which enhances 398 
locomotion (Kong et al., 2010). A significant reduction in dopaminergic neurons in the PPM1/2 cluster 399 
was only found at week 4 when impaired locomotion of G2019S flies was prominent. In a PD fly model 400 
involving SNCA overexpression and aux knockdown, dopaminergic neurons in the PPM1/2 cluster were 401 
selectively degenerated and this phenotype was accompanied by impaired locomotion in relatively young 402 
adult flies (Song et al., 2017). We postulate that the age-dependent impaired locomotion displayed by 403 
G2019S flies could be caused by gradual and differential loss of dopaminergic neurons in these clusters, 404 
thereby affecting different aspects of locomotion. However, further study is needed to test that hypothesis. 405 
Expression of the G2019S mutant protein induces Lrrk2 auto- and hyper-phosphorylation, as well as 406 
protein accumulation, together enhancing cellular Lrrk2 activity and causing aberrant downstream 407 
signaling (Sheng et al., 2012). We have shown here that neuronal expression of Lrrk2-G2019S reduced 408 
Akt phosphorylation (Figure 4A and B). Consistently, hyperactivated G2019S mutant protein impaired 409 
interaction with and phosphorylation of Akt, resulting in compromised signaling and accelerated 410 
neurodegeneration (Ohta et al., 2011; Panagiotakopoulou et al., 2020). However, WGE feeding restored 411 
downstream Akt signaling by suppressing G2019S mutant protein hyperactivation. Rab10, one of the 412 
best-characterized substrates for Lrrk2, mediates several of Lrrk2’s cellular functions (Karayel et al., 413 
2020). In Drosophila, Rab10 and Lrrk2-G2019S synergistically affect the activity of dopaminergic 414 
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neurons, mediating deficits in movement (Fellgett et al., 2021; Petridi et al., 2020). We have shown that 415 
WGE treatment downregulated levels of Lrrk2 accumulation and phosphorylated Rab10 (Figure 3F to H), 416 
thus alleviating their synergistic toxicity. Several kinase inhibitors have been developed to block the 417 
kinase activity of Lrrk2, including of both wild-type Lrrk2 and the G2019S mutant, which could affect 418 
endogenous Lrrk2 activity (Sheng et al., 2012). Instead, WGE treatment modulates the phosphorylation 419 
status and protein level of the G2019S mutant but not those of wild-type Lrrk2. The new hydrogen bond 420 
created at the Ser2019 autophosphorylation site may provide a docking site for some chemicals in WGE, 421 
representing a possible explanatory mechanism that warrants further study (Lang et al., 2015).  422 
The antioxidation and detoxification factor Nrf2 is a target of Akt activation. Nrf2 phosphorylation and 423 
HO-1 expression levels revealed that Nrf2 is inactivated in G2019S flies, but it was activated by WGE 424 
treatment (Figure 4C and D). Intriguingly, our genetic data indicate that Nrf2 primarily functions in the 425 
glia of G2019S flies, with Nrf2 depletion from glia eliminating the beneficial effects of WGE and glial 426 
Nrf2 activation partially substituting for WGE feeding (Figure 5B). Cortical neurons express much lower 427 
levels of Nrf2 than astrocytes owing to hypo-acetylation and transcriptional repression of the Nrf2 428 
promoter (Bell et al., 2015). Moreover, neurons express greater amounts of Cullin 3, the scaffold 429 
component of the E3 ubiquitin ligase that targets Nrf2 for proteasomal degradation (Jimenez-Blasco et al., 430 
2015). Both those mechanisms render neuronal Nrf2 inert to activation. Nrf2 activation in astrocytes 431 
maintains neuronal integrity and function against oxidative insults in response to stress by supplying 432 
antioxidants such as glutathione and HO-1 (Kraft et al., 2004; Vargas & Johnson, 2009). Previous study 433 
showed that 4-HBA triggers glia to secrete HO-1 via the Nrf2 pathway, protecting neurons from hydrogen 434 
peroxide in the primary culture (Luo et al., 2017). In PD models in which wild-type or mutant -435 
synuclein is overexpressed, activation of neuronal Nrf2 (Barone et al., 2011; Skibinski et al., 2017) or 436 
astrocytic Nrf2 (Gan et al., 2012) proved neuroprotective. In a previous study, lovastatin treatment 437 
provides neuroprotection in the G2019S-induced PD model, also through the Akt/Nrf2 pathway (C. H. 438 
Lin et al., 2016). As activation of neuronal Nrf2 plays a non-conventional role in promoting 439 
developmental dendrite pruning (Chew et al., 2021), it remains interesting to further study the cell types 440 
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that mediate the action of lovastatin. By genetically manipulating the G2019S fly model, we have shown 441 
that WGE-induced Nrf2 activation in glia but not in neurons protects dopaminergic neurons from 442 
degeneration and ameliorates impaired locomotion. 443 
Astrocyte-like and ensheathing glia are two major types of glia in the Drosophila nervous system, 444 
surrounding and also extending long processes into neuropils of the brain. These astrocyte-like glia 445 
exhibit a morphology and function similar to those of mammalian astrocytes, including reuptake of 446 
neurotransmitters and phagocytosis of neuronal debris (Freeman, 2015; Tasdemir-Yilmaz & Freeman, 447 
2014). Ensheathing glia of varying morphologies encase axonal tracts and neuropils, regulating neuronal 448 
excitability and participating in phagocytosis and injury-induced inflammation (Doherty et al., 2009; Otto 449 
et al., 2018). Thus, given their proximity to neurons and similar functions, it is not surprising that both 450 
types of glia collectively mediate the protective effects of WGE. 451 
Communication between neurons and glia maintains homeostasis, yet also confers the disease state 452 
during neurodegeneration. In the Drosophila G2019S model, upregulation of the BMP ligand Gbb in 453 
dopaminergic neurons activates Mad/Smad signaling in glia, which promotes neuronal degeneration via a 454 
feedback mechanism (Maksoud et al., 2019). Surprisingly, although the number of dopaminergic neurons 455 
in the fly brain is relatively small, the upregulated pMad signal spreads throughout the brain (Figure 7B), 456 
suggesting that BMP can be disseminated over long distances. In PD patients, higher levels of TGF-β1 457 
have been detected in the striatum and ventricular cerebrospinal fluid (Vawter et al., 1996). Thus, 458 
members of the TGF-β1 superfamily such as TGF-β1 and BMP signaling molecules may represent 459 
indicators of neuronal degeneration. Accordingly, disrupting the glia-to-neuron feedback mechanism may 460 
sustain neuronal survival. In glia, we found that WGE treatment downregulated the pMad levels that had 461 
been increased in the G2019S flies (Figure 7A and B). Nrf2 activation in glia also suppressed the 462 
enhanced levels of pMad in G2019S flies (Figure 8B and C). Indeed, our genetic assays indicate that the 463 
Nrf2 and Mad pathways interact in the glia of G2019S flies. Thus, WGE exerts its beneficial effects by 464 
activating Nrf2 to antagonize the Mad activity that would otherwise contribute to the degeneration of 465 
dopaminergic neurons. As a transcriptional activator, Nrf2 induces expression of the inhibitory 466 
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component Smad7 to form inactive Smad complexes (Song et al., 2019) and the phosphatase subunit 467 
PPM1A to alter Smad2/3/4 phosphorylation and DNA binding (Lin et al., 2006). Given that these 468 
components are conserved in Drosophila, Nrf2 may employ similar pathways to block Mad signaling in 469 
glia. 470 
That glial Nrf2 activation protects neurons is evidenced by our observations of enhanced HO-1 471 
expression (Figure 4C) and increased numbers of dopaminergic neurons (Figure 5C and D). These results 472 
support that the role of Nrf2 in glia is to induce expression of antioxidation building blocks, such as 473 
phase-II detoxification enzymes, and to enhance inflammatory processes (Hirrlinger & Dringen, 2010; 474 
Rojo et al., 2010). In a model of fibrosis, TGF-β/Smad2/3 suppressed expression of the ARE-luciferase 475 
reporter and gluthathion (Ryoo et al., 2014). Moreover, Nrf2 knockdown was shown to reduce expression 476 
of the antioxidative enzyme NAD(P)H quinone dehydrogenase 1 (NQO1), thereby elevating cellular 477 
oxidative stress and upregulating TGF-β/Smad targeted gene expression (Prestigiacomo & Suter-Dick, 478 
2018). Hence, we propose that WGE promotes Nrf2 activation to antagonize the Smad signaling in glia 479 
that is induced by dopaminergic neuron-secreted BMP/Gbb signal during degeneration. 480 
In our study, the LRRK2-G2019S mice show locomotor defects and dopaminergic loss at the age of 481 
11.5 months. A previous study shows only earlier signs of defects, the reduction of the dopamine level 482 
and release at the age of 12 months in the LRRK2-G2019S mice (Li et al, 2012), which could be 483 
contributed by the genetic background (FVB/NJ v.s. C57BL/6J). Nevertheless, we have demonstrated that 484 
feeding these mice with WGE rescues their locomotor coordination, suppresses their centrophobism, and 485 
recovers their numbers of dopaminergic neurons and hyperactivated microglia (Figure 9, and Figure 10A 486 
to D). Significantly, we found that activity of the TGF-β/Smad2/3 pathway was elevated in nigrostriatal 487 
brain lysates, and this activity was also suppressed by WGE treatment (Figure 10E and G). Collectively, 488 
these results from fly and mouse PD models indicate that the effectiveness of WGE is likely mediated 489 
through conserved Nrf2/Mad pathways (Figure 11). Our findings contribute to our mechanistic 490 
understanding of PD and provide potential therapeutic strategies that incorporate the traditional herbal 491 
medicine GE. 492 
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Materials and Methods 493 
Drosophila stocks and maintenance  494 
All fly stocks were maintained on standard cornmeal-based food medium at 25°C. Drosophila stocks 495 
sourced from the Bloomington Drosophila Stock Center (Indiana University, Bloomington, USA) were: 496 
UAS-mCD8-GFP (#5137), elav-GAL4 (#8760), repo-GAL4 (#7215), Ddc-LexA (#54218), UAS-cncTRiP 497 
(#25984), Tub-GAL80ts (#7108), alrm-GAL4 (#67032), R56F03-GAL4 (#39157), UAS-tkvQ253D (#36536), 498 
and MadK00237 (#10474). NP2222-GAL4 (#112830) was from the Drosophila Genomics Resource Center 499 
and NP6293-GAL4 (#105188) was from the Kyoto Stock Center. Other stocks include UAS-Flag-LRRK2-500 
WT (Lin et al., 2010), UAS-Flag-LRRK2-G2019S (Lin et al., 2010), Ddc-GAL4 (Sang et al., 2007), ARE-501 
GFP (Sykiotis & Bohmann, 2008),  UAS-cncC-FL2 (Sykiotis & Bohmann, 2008), moody-GAL4 (Bainton 502 
et al., 2005), and UAS-Mad (Takaesu et al., 2006). The two LexAop fly lines—LexAop-LRRK2-WT and 503 
LexAop-LRRK2-G2019S—were generated in this study. In brief, the cDNAs for LRRK2-WT and LRRK2-504 
G2019S were isolated from the pDEST53-LRRK2-WT and pDEST53-LRRK2-G2019S plasmids 505 
(Addgene, Massachusetts, USA) for subcloning into LexAop plasmids (Addgene, Massachusetts, USA), 506 
which were for microinjection (Fly facility, University of Cambridge, UK). The transgenes were site 507 
landed at an attP site on the 2nd chromosome (25C6). For temperature-shift assay of GAL80ts flies, 508 
parental flies were maintained at 19°C and allowed to mate, before collecting the F1 adults and shifting 509 
them to 29°C to inactivate GAL80. 510 
 511 
Preparation of WGE and related chemical compounds 512 
Authentication of GE and preparation of WGE were as described previously (Lin et al., 2018; Y. E. 513 
Lin et al., 2016). WGE (KO DA Pharmaceutical Co. Ltd., Taoyuan, Taiwan), gastrodin (Wuhan YC Fine 514 
Chemical Co., Wuhan, China), and 4-HBA (Sigma-Aldrich, Darmstadt, Germany) were added to freshly-515 
prepared cornmeal-based fly food at indicated final concentrations (w/w). For experiments, one- to three-516 
day-old post-eclosion flies were collected and transferred to fresh food medium twice per week. 517 
 518 
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Fly locomotion assay 519 
A negative geotaxis climbing assay was performed to assess locomotor activity, and it was 520 
conducted according to a previous study with minor modification (Madabattula et al., 2015). Cohorts of 521 
35 flies from each genotype were assayed weekly for six consecutive weeks. Success rates were 522 
calculated as the percentage of flies that could climb above the 8-cm mark of a 20-cm cylinder within 10 523 
s.   524 
The free-walking assay protocol was conducted based on a previous report with minor modification 525 
(Chen et al., 2014). Cohorts of eight flies were habituated on a 10-cm agar-filled dish for 30 min. The 526 
dishes were gently tapped to encourage the flies to walk, which was video-taped for 5 min. Movement 527 
tracks were processed in ImageJ and quantified using the Caltech multiple fly tracker (Ctrax). 528 
 529 
Immunostaining and immunoblotting of adult fly brains 530 
The protocol for immunostaining whole-mount adult brains was essentially as described previously 531 
(Lin et al., 2010; Maksoud et al., 2019). Adult fly brains for each genotype were dissected at the indicated 532 
time-points for immunostaining with the following primary antibodies: mouse anti-TH (Immunostar, 533 
22941, 1:1000); mouse anti-repo (Hybridoma Bank DSHB, 8D12, 1:500); chicken anti-GFP (Abcam, 534 
ab13970, 1:10000); and rabbit anti-phospho-Smad3 (Ser423/425) (Abcam, ab52903, 1:250) (Smith et al., 535 
2012). Fluorophore-conjugated secondary antibodies were: FITC-conjugated goat anti-mouse IgG 536 
(Jackson ImmunoResearch, AB_2338589, 1:500); Alexa Fluor 488-conjugated goat anti-mouse IgG 537 
(Invitrogen, A28175, 1:500); Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, 538 
AB_2338680, 1:500); Alexa Fluor 488-conjugated goat anti-rabbit IgG (Invitrogen, A27034, 1:500); and 539 
Cy5-conjugated goat anti-rat IgG (Invitrogen, A10525, 1:500). Phalloidin-TRITC (Sigma-Aldrich, 540 
P1951, 1:5000) that binds F-actin was also used for counterstaining. Immunofluorescence signals were 541 
acquired under confocal microscopy (ZEISS LSM 710, Germany).  542 
Adult brain extracts were prepared according to a previously described protocol (Lin et al., 2010). In 543 
brief, ~80 fly heads for each genotype were isolated for extract preparation. Equivalent amounts of 544 
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samples (30 μg/20 μL/well) were resolved by SDS-PAGE for immunoblotting. The following primary 545 
antibodies were used: rabbit anti-human LRRK2 (Abcam, ab133474, 1:1000); rabbit anti-phospho-546 
LRRK2 (Ser1292) (Abcam, ab203181, 1:500); rabbit anti-Akt (Cell Signaling, #4691, 1:1000); rabbit anti-547 
Drosophila phospho-Akt Ser505 (Cell Signaling, #4054, 1:500); rabbit anti-Nrf2 (Thermo Fisher 548 
Scientific, 710574, 1:1000); rabbit anti-phospho-Nrf2 (Ser40) (Thermo Fisher Scientific, PA5-67520, 549 
1:1000); mouse anti-HO-1-1 (Thermo Fisher Scientific, MA1-112, 1:1000); rabbit anti-GAPDH 550 
(GeneTex, GTX100118, 1:5000); and rabbit anti-alpha tubulin (Cell Signaling, #2144, 1:10000), 551 
followed by blotting with secondary antibodies peroxidase-conjugated goat anti-rabbit IgG (Jackson 552 
ImmunoResearch, AB_2307391, 1:7500) and peroxidase-conjugated goat anti-mouse IgG (Jackson 553 
ImmunoResearch, AB_10015289, 1:7500). 554 
 555 
ARE-GFP reporter assay 556 
The antioxidant response element (ARE)-GFP reporter assay was a modification of the protocol 557 
from a previous study (Sykiotis & Bohmann, 2008). ARE-GFP flies of one week old (for Figure 5-figure 558 
supplement 1) or 6 weeks old (Figure 6) were fed with regular food or food containing 0.1% WGE prior 559 
to brain dissection and GFP immunostaining. To quantify ARE-GFP in the 6-week-old adult fly brain, 560 
confocal images were processed in ImageJ. Mean GFP fluorescence intensities in mCherry-labeled glial 561 
cells and TH-positive dopaminergic neurons of the PPL1 cluster were quantified and normalized as 562 
GFP/mCherry. 563 
 564 
Animal care and treatments 565 
Transgenic LRRK2-G2019S mice were purchased from the Jackson Laboratory (JAX stock #009609, 566 
Bar Harbor, ME, USA) and they were maintained at the animal center of the National Taiwan University 567 
Hospital (NTUH). Non-transgenic (nTg) and heterozygous transgenic LRRK2-G2019S mice were 568 
obtained by crossing heterozygous LRRK2-G2019S mice with wild-type FVB/NJ mice (JAX stock 569 
#001800). Mice at 8.5 months-old were assigned to one of three groups (5 to 6 mice per group): nTg, 570 
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LRRK2-G2019S, and LRRK2-G2019S fed with WGE (0.5 g/kg body weight per day) (Lin et al., 2018) for 571 
three months.  572 
 573 
Behavioral assays  574 
We employed two behavioral tests to assay mouse motor function, i.e., an open field assay to assess 575 
spontaneous locomotor activity and CatWalk XT gait analysis to assay coordination. Behavioral 576 
experiments were conducted blind to genotype, as described previously (Lin et al., 2020).  577 
 578 
Immunohistochemical staining  579 
After three months of WGE treatment, mice were sacrificed at the age of 11.5 months. The 580 
substantia nigra and striatum were dissected out. The substantia nigra was subjected to immunostaining, 581 
as described previously (Lin et al., 2020). Anti-tyrosine hydroxylase (TH) (Millipore, AB152, 1:200) and 582 
anti-ionized calcium-binding adapter molecule 1 (Iba-1) (GeneTex, GTX100042, 1:200) were used as 583 
primary antibodies for 24 h at 4°C. Secondary antibodies were DyLight 488 goat anti-rabbit 1:300 and 584 
Alexa Fluor 546 goat anti-rabbit at 1:200 (25°C for 1 h). Mounting medium with DAPI (GeneTex, 585 
GTX30920) was used as a counterstain.  586 
 587 
Immunoblotting  588 
Frozen nigrostriatal brain tissues were homogenized and mixed with lysis buffer to determine 589 
protein content and for immunoblotting, as described previously (Lin et al., 2020). The membrane was 590 
incubated overnight at 4°C with the following primary antibodies: anti-LRRK2 (Abcam, ab133474, 591 
1:5000); anti-phospho-LRRK2 (Ser1292, Abcam, ab203181, 1:1000); anti-Smad2 (Cell Signaling, #5339, 592 
1:1000); anti-phospho-Smad2 (Ser465/467, Cell Signaling, #3108, 1:1000); anti-Smad3 (Cell Signaling, 593 
#9523, 1:1000); anti-phospho-Smad3 (Ser423/425, Abcam, ab52903, 1:1000); and anti-beta actin 594 
(Sigma-Aldrich, A5441, 1:5000). After washing, peroxidase-conjugated goat anti-rabbit IgG (GeneTex, 595 
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GTX213110-01, 1:5000) or peroxidase-conjugated goat anti-mouse IgG (GeneTex, GTX213111-01, 596 
1:5000) were used as secondary antibodies.  597 
 598 
Statistical Analysis 599 
All statistical analyses were carried out in GraphPad PRISM 6 (La Jolla, CA, USA). Data are 600 
presented as mean ± standard error (SEM). Statistical analysis was performed using either student t-test or 601 
one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test. P values less than 602 
0.05 (p < 0.05) were considered indicative of significance. For exact n numbers, p values, F values, t-603 
values, and degrees of freedom of each statistical test, please see the statistical information in the 604 
Additional file-Supporting file 1. 605 
  606 
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Figure legends 924 
Figure 1. WGE treatment rescues the diminished locomotion of Ddc>G2019S flies. 925 
(A to C) Climbing activities of Ddc>G2019S flies fed on food supplemented with 0.1%, 0.5% or 1.0% 926 
WGE (A), 0.1 or 1.0 mM gastrodin (B), and 0.1 or 1.0 mM 4-HBA (C). Controls are Ddc>Lrrk2 and 927 
Ddc>G2019S flies fed regular food. Bar graphs show the percentages of flies (mean ± SEM, N = 6) that 928 
climbed above 8 cm within 10 sec. (D) Five-minute walking tracks pooled from eight flies each of the 929 
Ddc>Lrrk2, Ddc>G2019S, and Ddc>G2019S + 0.1% WGE groups at week 4. Bar graph at right 930 
summarizes their walking distances (mean ± SEM, N = 8). One-way analysis of variance (ANOVA) with 931 
Tukey’s post-hoc multiple comparison test: * p < 0.05, ** p < 0.01, and *** p < 0.001, ns, not significant. 932 
 933 
Figure 1-figure supplement 1. Climbing activity assay of Ddc>mCD8-GFP and Ddc>Lrrk2 flies. 934 
(A) Comparable climbing activities were detected for Ddc>mCD8-GFP and Ddc>Lrrk2 flies. Both 935 
exhibited better climbing activities than Ddc>G2019S flies in the climbing assay from week 1 to 6. Bar 936 
graph shows percentage (mean ± SEM, N = 5) of flies that successfully climbed above 8 cm within 10 937 
sec. One-way analysis of variance (ANOVA) and Tukey’s post-hoc multiple comparison test: * p < 0.05, 938 
*** p < 0.001, ns, not significant. (B) Ddc>G2019S flies fed with 0.02% or 0.1% WGE exhibited 939 
improved climbing activity (mean ± SEM, N = 6). One-way ANOVA and Tukey’s post-hoc multiple 940 
comparison test: * p < 0.05, *** p < 0.001 (relative to Ddc>G2019S); and ## p < 0.01, ### p < 0.001 941 
(comparing different doses of WGE), ns, not significant.  942 
 943 
Figure 1-figure supplement 2. Locomotion improvement of Ddc>G2019S flies starting WGE feeding 944 
at week 4. 945 
The climbing activities of Ddc>Lrrk2, Ddc>G2019S, and Ddc>G2019S with 0.1% WGE feeding at week 946 
4 were assessed at weeks 3, 4, 5 and 6. Bar graphs show success rates (mean ± SEM, N = 6) of flies 947 
climbing over 8 cm height in 10 sec. One-way ANOVA and Tukey’s post-hoc multiple comparison test 948 
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were performed and statistical significance was shown as *** for p < 0.001, * for p < 0.05 and ns for no 949 
significance. 950 
 951 
Figure 2. WGE prevents loss of dopaminergic neurons in Ddc>G2019S flies. 952 
(A) Representative adult brain images showing TH-positive dopaminergic neurons in the PPL1 cluster of 953 
2-, 4-, and 6-week-old flies of the Ddc>Lrrk2, Ddc>G2019S, and 0.1% WGE-fed Ddc>G2019S groups. 954 
Scale bar: 10 μm. (B) Average numbers (mean ± SEM, N = 5) of TH-positive dopaminergic neurons in 955 
the PPL1, PPM1/2, PPL2, and PPL3 clusters per brain hemisphere. One-way ANOVA with Tukey’s post-956 
hoc multiple comparison test: * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. 957 
 958 
Figure 2-figure supplement 1. WGE treatment prevents dopaminergic neuron loss in Ddc>G2019S 959 
flies. 960 
(A to C) Representative adult whole-brain images for TH staining to reveal dopaminergic neurons in the 961 
PPL1, PPL2, PPM1/2 and PPM3 clusters of 2-, 4-, and 6-week-old flies. Scale bar: 40 μm. The images 962 
for the PPL1 cluster are shown as enhanced views of the dashed boxes in Fig. 2. 963 
 964 
Figure 3. WGE modulates Lrrk2 accumulation and hyperactivation in elav>G2019S flies. 965 
(A) Representative immunoblots of 3-day-old adult brain lysates showing expression levels of Lrrk2, 966 
pLrrk2 (phosphoryled at Ser1292), Akt, and pAkt (phosphorylated at Ser505) in elav>Lrrk2 and 967 
elav>G2019S flies. (B and C) Quantifications (mean ± SEM, N = 3) of Lrrk2 and pLrrk2/Lrrk2 (B), and 968 
Akt and pAkt/Akt (C). (D) Representative immunoblots of 2- and 4-week-old adult brain lysates showing 969 
Lrrk2 levels in the fly groups elav>Lrrk2, elav>G2019S, and elav>G2019S fed with 0.1% WGE. (E) 970 
Quantification of Lrrk2 levels in 2- and 4-week-old adult brains (mean ± SEM, N = 3). (F) Representative 971 
immunoblots of 4-week-old adult brain lysates showing expression levels of Lrrk2, pLrrk2, Rab10 and 972 
pRab10 (phosphorylated at Thr73). (G and H) Quantification (mean ± SEM, N = 3) of levels of Lrrk2 and 973 
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pLrrk2/Lrrk2 (G), and of Rab10 and pRab10/Rab10 (H). One-way ANOVA with Tukey’s post-hoc 974 
multiple comparison test: * p < 0.05, ** p < 0.01, ns, not significant. 975 
 976 
Figure 3-figure supplement 1. WGE specifically modulates Lrrk2 accumulation and 977 
hyperactivation in elav>G2019S but not elav>Lrrk2 flies. 978 
(A) Representative immunoblots of 2-week-old adult brain lysates showing levels of Lrrk2 and pLrrk2 979 
(Ser1292) in elav>Lrrk2, WGE-fed elav>Lrrk2, elav>G2019S and WGE-fed elav>G2019S flies. (B and 980 
C) Quantification (mean ± SEM, N = 3) of Lrrk2 (B) and pLrrk2/Lrrk2 (C) levels. One-way ANOVA and 981 
Tukey’s post-hoc multiple comparison test: * p < 0.05, *** p < 0.001, ns, not significant. 982 
 983 
Figure 4. WGE activates the Akt-Nrf2 pathway in elav>G2019S flies. 984 
(A) Representative immunoblots of 2- and 4-week-old adult brain lysates showing levels of Akt and pAkt 985 
in brain extracts of elav>Lrrk2, elav>G2019S, and WGE-fed elav>G2019S flies. (B) Quantification 986 
(mean ± SEM, N = 3) of pAkt/Akt levels in 2- and 4-week-old adult brains. (C) Representative 987 
immunoblots of 4-week-old adult brain lysates showing levels of Nrf2, pNrf2 (phosphorylated at Ser40), 988 
GSK3, pGSK3 (phosphorylated at Ser9), and HO-1 in elav>Lrrk2, elav>G2019S, and WGE-fed 989 
elav>G2019S flies. GADPH acted as a loading control in (A) and (C). (D) Quantification (mean ± SEM, 990 
N = 3) of relative protein levels to respective Nrf2, GSK3β, and HO-1. One-way ANOVA with Tukey’s 991 
post-hoc multiple comparison test (relative to elav>G2019S): * p < 0.05, ** p < 0.01, *** p < 0.001, ns, 992 
not significant. 993 
 994 
Figure 5. Activation of Nrf2 in glia rescues locomotion defects in Ddc>G2019S flies.  995 
(A and B) Requirement of Nrf2 in glia but not neurons for WGE-improved Ddc>G2019S climbing 996 
activity. (A) Climbing success rates of flies in which Ddc-GAL4 drives co-expression of Lrrk2-G2019S 997 
and mCD8-GFP, cncC-FL2 or cnc-RNAi. As a control line, Ddc-GAL4 drives co-expression of Lrrk2 and 998 
mCD8-GFP. (B) Climbing success rates of flies in which Ddc-LexA drives wild-type Lrrk2 or Lrrk2-999 
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G2019S expression and repo-GAL4 drives cncC-FL2 or cnc-RNAi expression (mean ± SEM, N = 6 for 1000 
(A) and (B)). WGE was added to food at a concentration of 0.1% (w/w). (C) Adult brain images showing 1001 
TH-positive dopaminergic neurons in the PPL1 clusters of 6-week-old Ddc-LexA>Lrrk2 or Ddc-1002 
LexA>G2019S flies with repo-GAL4 control or repo-GAL4-driven cncC-FL2 or cnc-RNAi expression. 1003 
Scale bar: 10 μm. (D) Average numbers (mean ± SEM, N = 5) of TH-positive dopaminergic neurons in 1004 
PPL1 clusters per brain hemisphere are shown. One-way ANOVA with Tukey’s post-hoc multiple 1005 
comparison test (relative to Ddc>G2019S (A) or Ddc-LexA>G2019S; repo-GAL4 (B and D)): ** p < 1006 
0.01, *** p < 0.001, ns, not significant.  1007 
 1008 
Figure 5-figure supplement 1. WGE treatment specifically activates glial Nrf2 signals in the ARE-1009 
GFP reporter flies. 1010 
(A and B) WGE treatment activates glial Nrf2 signals in one-week-old ARE-GFP reporter flies. ARE-1011 
GFP (green) and glial Repo (red) in whole-mount adult brains without (A) or with 0.1% WGE treatment 1012 
(B) for 5 days. Phalloidin (in blue) reveals brain structures. White arrowheads indicate GFP signals. Scale 1013 
bar: 50 μm. Dotted boxes are enhanced views and shown as separate channels at right. 1014 
 1015 
Figure 5-figure supplement 2. WGE rescues the locomotion defect displayed by Ddc-LexA>G2019S 1016 
flies. 1017 
WGE treatment improves the climbing ability of Ddc-LexA>G2019S flies. Bar graph shows percentage 1018 
(mean ± SEM, N = 6) of flies that successfully climbed above 8 cm within 10 sec. One-way ANOVA and 1019 
Tukey’s post-hoc multiple comparison test (relative to Ddc-LexA>G2019S): * p < 0.05, ** p < 0.01, *** 1020 
p < 0.001. 1021 
 1022 
 1023 
Figure 6. Nrf2 in astrocyte-like and ensheathing glia mediates the effect of WGE treatment in 1024 
Ddc>G2019S flies. 1025 
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(A) Nrf2 knockdown in astrocyte-like and ensheathing glia abolishes the improved locomotion elicited by 1026 
WGE treatment in Ddc>G2019S flies. Composite bar graph shows climbing success rates for 6-week-old 1027 
Ddc-LexA>G2019S flies with cnc-RNAi driven by repo-GAL4 in all glia, alrm-GAL4 in astrocyte-like 1028 
glia, np2222 in cortex glia, np6293 in perineurial glia, R56F03 in ensheathing glia, and moody-GAL4 in 1029 
subperineurial glia. (B) Composite bar graph shows climbing success rates (mean ± SEM, N = 6) for 6-1030 
week-old Ddc-LexA>G2019S flies with overexpression of Nrf2 in astrocyte-like glia (alrm>cncC-FL2) 1031 
or ensheathing glia (R56F03>cncC-FL2). One-way ANOVA and Tukey’s post-hoc multiple comparison 1032 
test (relative to Ddc-LexA>G2019S; GAL4>cnc-RNAi (A) or Ddc-LexA>G2019S; GAL4 (B)): * p < 0.05, 1033 
*** p < 0.001, ns, not significant. (C and E) Representative images showing expression of ARE-GFP in 1034 
astrocyte-like glia (alrm>mCherry) (C) and ensheathing glia (R56F03>mCherry) (E), together with TH-1035 
positive dopaminergic neurons in the PPL1 clusters of 6-week-old Ddc-LexA>Lrrk2, Ddc-LexA>G2019S, 1036 
or WGE (0.1% w/w)-fed Ddc-LexA>G2019S flies. Bar: 5 μm. GFP channels in the dashed boxes are 1037 
shown as enhanced views in the lower panel, with glial signals labeled by dashed lines. (D and F) 1038 
Quantifications (mean ± SEM, n > 25 for each genotype) of GFP intensities in astrocyte-like glia (D) or 1039 
ensheathing glia (F). GFP intensities in glia have been outlined manually using the mCherry-positive 1040 
signals. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to Ddc-1041 
LexA>G2019S; alrm>mCherry (D) or Ddc-LexA>G2019S; R56F03>mCherry (F)): * p < 0.05, *** p < 1042 
0.001, ns, not significant. 1043 
 1044 
Figure 6-figure supplement 1. Lrrk2 and pLrrk2 levels are maintained upon glial Nrf2 1045 
overexpression. 1046 
(A) Representative immunoblots of 2-week-old adult brain lysates showing protein expression levels of 1047 
Lrrk2 and pLrrk2 (Ser1292) in Ddc-LexA>G2019S; repo-GAL4 and Ddc-LexA>G2019S; repo>cncC-FL2 1048 
flies. (B and C) Quantification of Lrrk2 (B) and pLrrk2/Lrrk2 (C) (mean ± SEM, N = 3). Student t-test: 1049 
ns, not significant. 1050 
 1051 
 42 
Figure 6-figure supplement 2. WGE treatment induces a mild Nrf2 activation in dopaminergic 1052 
neurons in Ddc>G2019S flies. 1053 
(A and B) Quantifications (mean ± SEM, n > 20 for each genotype) of GFP intensities in TH-positive 1054 
dopaminergic neurons nearby the astrocyte-like glia (A) or ensheathing glia (B). GFP intensities were 1055 
measured within dopaminergic neurons outlined by the TH-positive signals and were normalized to 1056 
mCherry intensities. One-way ANOVA and Tukey’s post-hoc multiple comparison test with reference to 1057 
Ddc-LexA>G2019S; alrm>mCherry (A) or Ddc-LexA>G2019S; R56F03>mCherry (B) were performed 1058 
and shown as ** for p < 0.01, *** for p < 0.001, and ns for no significance. 1059 
 1060 
Figure 7. WGE down-regulates G2019S-induced BMP/Mad signaling. 1061 
(A) Representative images of glial pMad staining in the adult PPL1 clusters of Ddc>Lrrk2, 1062 
Ddc>G2019S, and WGE-fed Ddc>G2019S flies. White arrows indicate pMad signals co-localized with 1063 
Repo, with single channels for pMad signals shown as insets. Bar: 10 μm. (B) Quantification (mean ± 1064 
SEM, n > 60 for each genotype) of pMad signals normalized to Repo levels in glia of the indicated 1065 
genotypes. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to Ddc>G2019S): 1066 
*** p < 0.001. (C and D) Climbing success rates (mean ± SEM, N = 10) at weeks 1-4 demonstrating that 1067 
WGE treatment rescues locomotion deficits induced by glial overexpression of Mad (C) or tkvQ253D (D) in 1068 
Tub-GAL80
ts
; repo-GAL4 flies. One-way ANOVA and Tukey’s post-hoc multiple comparison test 1069 
(relative to repo>Mad or repo>tkvQ253D): ** p < 0.01, *** p < 0.001. (E and G) Representative images of 1070 
4-week-old adult brain showing TH staining of the PPL1 clusters of Tub-GAL80ts; repo-GAL4, Tub-1071 
GAL80
ts




Q253D, and WGE-fed Tub-GAL80ts; repo>tkvQ253D flies (G). Bars: 12.5 μm. (F and 1073 
H) Bar graphs show mean ± SEM (N = 5) of TH-positive dopaminergic neurons in the PPL1 clusters of 1074 
4-week-old flies. One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to Tub-1075 
GAL80
ts
; repo>Mad (F) or Tub-GAL80ts; repo>tkvQ253D (H)): *** p < 0.001. 1076 
 1077 
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Figure 7-figure supplement 1. Mad heterozygosity rescues the impaired locomotion of Ddc>G2019S 1078 
flies.  1079 
Removing one copy of Mad improves Ddc>G2019S climbing activity. Bar graphs show climbing success 1080 
rates (mean ± SEM, N = 6) of 6-week-old Ddc>Lrrk2, Ddc>G2019S, and Ddc>G2019S, Mad-/+ flies. 1081 
One-way ANOVA and Tukey’s post-hoc multiple comparison test (relative to Ddc>G2019S): *** p < 1082 
0.001. 1083 
 1084 
Figure 8. Nrf2 antagonizes BMP/Mad signaling in glia. 1085 
(A) Heterozygosity of Mad suppresses G2019S mutation-induced locomotion impairment in a negative 1086 
geotaxis assay. Bar graph shows percentages (mean ± SEM, N = 6) of 6-week-old flies that climbed 1087 
above 8 cm within 10 sec. One-way ANOVA and Tukey’s post-hoc multiple comparison test: * p < 0.05, 1088 
** p < 0.01, *** p < 0.001, ns, not significant. (B) Representative images of pMad staining in the adult 1089 
brains of Ddc-LexA>Lrrk2 or Ddc-LexA>G2019S flies in which repo-GAL4 drives expression of cncC-1090 
FL2 or cnc-RNAi. Impact of WGE treatment is shown in the rightmost panels. Arrows indicate pMad and 1091 
Repo dual-positive cells. Insets are enlarged images of the dashed boxes, and dashed lines encompass 1092 
Repo-positive cells. Bar: 20 μm. (C) Quantification of the ratio of pMad to Repo (mean ± SEM, N > 40). 1093 
One-way ANOVA and Tukey’s post-hoc multiple comparison test: *** p < 0.001, ns, not significant. (D) 1094 
Images show pan-glial ARE-GFP expression (repo>mCherry) in Ddc-LexA>Lrrk2, Ddc-LexA>G2019S, 1095 
and Ddc-LexA>G2019S, Mad+/- fly brains. GFP channels within the dashed boxes are shown as enhanced 1096 
views in the inset, with glial signals outlined by dashed lines. Bar: 20 μm. (E) Quantification for GFP 1097 
expression levels (mean ± SEM, n > 13). One-way ANOVA and Tukey’s post-hoc multiple comparison 1098 
test: * p < 0.05, *** p < 0.001. 1099 
 1100 
Figure 9. WGE treatment rescues impaired locomotion of LRRK2-G2019S mice. 1101 
(A) Video-tracked paths for nTg, LRRK2-G2019S and WGE-fed LRRK2-G2019S mice (8.5 and 11.5 1102 
months old) during the open-field test. (B) Quantification of total distance (meters, m), average velocity 1103 
 44 
(centimeters per sec, cm/s), and percentage moving time for 8.5, 9.5, 10.5 and 11.5 months old mice. (C) 1104 
Captured and converted images of single stance for each paw of 11.5-month-old nTg, LRRK2-G2019S 1105 
and WGE-fed LRRK2-G2019S mice in a catwalk analysis. (D) Quantification of stride length for each 1106 
paw of 8.5- and 11.5-month-old mice. Data in (B and D) are presented as mean ± SEM (nTg; N = 5, 1107 
G2019S; N = 6, WGE-fed G2019S; N = 6). One-way ANOVA and Tukey’s post-hoc multiple comparison 1108 
test: * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. RF – right front; RH – right hind; LF – left 1109 
front; LH – left hind. 1110 
 1111 
Figure 10. WGE prevents dopaminergic neuron loss, microglial activation, and phosphorylation of 1112 
LRRK2, Smad2, and Smad3.  1113 
(A and C) Representative images showing TH-positive dopaminergic neurons (A) or Iba-1-positive 1114 
microglia (C) in the substantia nigra of 11.5-month-old nTg, LRRK2-G2019S and WGE-fed LRRK2-1115 
G2019S mice. Bars: 100 μm in (A) and 50 μm in (C). (B and D) Quantification of numbers of TH-1116 
positive (B) or Iba-1-positive cells (D) relative to DAPI cells. (E) Representative immunoblots of 1117 
nigrostriatal lysates prepared from 11.5-month-old nTg, LRRK2-G2019S and WGE-fed LRRK2-G2019S 1118 
mice reveal expression levels of LRRK2, pLRRK2 (Ser1292), Smad2, pSmad2 (Ser465 and Ser467), Smad3, 1119 
and pSmad3 (Ser423 and Ser425). Actin acted as a loading control. (F and G) Quantifications of LRRK2 1120 
and pLRRK2/LRRK2 (F), as well as pSmad2/Smad2 and pSmad3/Smad3 (G). Data in (B, D, F, G) are 1121 
presented as mean ± SEM (N = 3). One-way ANOVA and Tukey’s post-hoc multiple comparison test: * 1122 
p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. 1123 
 1124 
Figure 10-figure supplement 1. WGE suppresses microglia activation in LRRK2-G2019S mice.  1125 
Single channel images of Figure 10C show Iba-1-positive microglia in the substantia nigra of 11.5-1126 
month-old nTg, LRRK2-G2019S and WGE-fed LRRK2-G2019S mice. Bars: 50 μm. 1127 
 1128 
Figure 11. The proposed model of WGE in the G2019S-induced neurodegeneration.  1129 
 45 
Accumulation of the hyperactivated G2019S mutant protein enhances the BMP ligand (Gbb) maturation 1130 
via up-regulation of Furin 1 translation in dopaminergic neurons. Secreted Gbb binds to the BMP 1131 
receptor, Tkv, and turns on Mad signaling in glia. The G2019S mutation also decreases the Nrf2 activity 1132 
in the brain, particularly in glia. Both up-regulated Mad and down-regulated Nrf2 pathways contribute to 1133 
neurodegeneration. WGE feeding suppresses G2019S hyperactivation in neurons and restores Nrf2 1134 
activity mostly in the astrocyte-like and ensheathing glia. WGE-elevated Nrf2 activity in glia antagonizes 1135 
the BMP/Mad signaling and initiates Nrf2/HO-1 axis in glia, attenuating the stress signals from glia and 1136 
promoting neuroprotection. Red and green solid arrows () indicate the observed effects exerted by 1137 
G2019S overexpression and WGE feeding, respectively, in the present study. Red and green dashed 1138 
arrows (-->) indicate the proposed actions trigged by Mad signaling and WGE feeding, respectively. Red 1139 
and green blunt-ended lines (---|) indicate the proposed inhibitions by Mad and Nrf2 overexpression, 1140 
respectively. (P) indicates phosphorylation. The Furin 1-mediated Gbb pathway labeled in gray is 1141 
modified from previous findings (Maksoud et al., 2019).  1142 
 1143 
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Figure 1-figure supplement 1
































1. Ddc>Lrrk2 at week 3, 4, 5 and 6
2. Ddc>G2019S at week 3, 4, 5 and 6
3. Ddc>G2019S at week 3 and starting 0.1% WGE feeding at week 4
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3. G2019S; mCD8-GFP + WGE
6. G2019S; cnc-RNAi + WGE
3. G2019S; repo-GAL4 + WGE
6. G2019S; repo>cnc-RNAi + WGE
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Figure 6-figure supplement 1
Figure 6-figure supplement 2
1. Lrrk2
2. G2019S







































3. G2019S + WGE
A B











































































































































































































































































































1 2 3 4 5
Lrrk2 G2019S G2019S

















































































































































































































RF RH LF LH
8.5 M 11.5 M
C
D









ns nsns ns ns ns ns ns


















































































































































































Figure 10-figure supplement 1
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